Drug Trial Radar · NCT04214197
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Feb 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Feb 3, 2020
Primary completion
Jul 2021
Study completion Aug 2021
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Jan 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic dermatitis. Crisaborole ointment 2% will be applied topically twice daily for four weeks and progress will be assessed by photography and patient-reports.
Conditions
- Atopic Dermatitis
Interventions
Crisaborole 2% Top OintDrug
Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to success (in days) on ISGATime frame: At days 1, 8,15, 21 and 29
- Time to success (by week) on ISGATime frame: At days 1, 8,15, 21 and 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MGH Clinical Unit for Research Trials in Skin (CURTIS)
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.